The kidneys play a crucial role in maintaining our overall health and well-being. Their primary function is to filter toxins from the blood and convert waste into urine. As we age, kidney function naturally declines, and chronic kidney disease (CKD) can develop, resulting in incomplete or insufficient removal of waste products. CKD is a progressive condition that affects more than 10% of the global population, totaling over 800 million individuals⁽²⁾. In the realm of kidney health, SynForU™ Remain, lactobacilli probiotic formulation, has demonstrated its efficacy and earned well-deserved recognition through an innovation award. Its positive impact on kidney health has been observed, further emphasizing its potential as a valuable asset in promoting well-being.
 
Gut microbiota vs kidney disease
The gut microbiome and kidney disease are closely interlinked. The gut-kidney axis refers to the bidirectional interaction between intestinal and renal functions. Kidney diseases can disrupt the structure of the gut microbiota, leading to dysbiosis. This dysbiosis, coupled with gastrointestinal disorders, can cause the translocation of microbial compounds with proinflammatory and nephrotoxic properties⁽⁴⁾. Gut dysbiosis plays a significant role in the progression of chronic kidney disease (CKD), therefore, microbiota-based strategies could be considered as innovative therapeutic and preventative approaches ⁽¹⁾.
 
Probiotic solution for kidney health
SynForU™ Remain, a composition of lactobacilli probiotics including Lactobacillus paracasei LP1411 (MFM 18) and Lactobacillus plantarum LP1410 (MFM 30-3), has emerged as a potential solution for kidney care. In a study conducted by Huang and colleagues using a CKD mouse model, SynForU™ Remain demonstrated significant improvements in kidney function. It reduced kidney injury and fibrotic-related proteins, alleviated oxidative stress and proinflammatory reactions, and enhanced immune responses within the kidneys. Notably, SynForU™ Remain reversed gut dysbiosis, restoring the abundance of beneficial bacteria, especially SCFA producers. This restoration improved the integrity of the intestinal barrier by modulating microbial composition and metabolite production. These findings suggest that SynForU™ Remain could be an effective preventive approach against CKD ⁽¹⁾.
 
Innovating the future of probiotics
As a recognition of its innovation and potential impact on kidney care, SynForU™ Remain has been awarded with the 19th National Innovation Award. The award acknowledges the role of innovative probiotic solutions in addressing the challenges posed by CKD and further reinforces the need for microbiota-based therapeutic and preventative strategies. The continued development and application of SynForU™ Remain and probiotic solutions pave the way for a brighter future in kidney health, offering hope for millions of individuals worldwide.